OSR Holdings Inc (OSRH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, OSR Holdings Inc (OSRH) has a cash flow conversion efficiency ratio of -0.019x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.42 Million) by net assets ($124.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see OSRH market cap for the company's overall valuation and market capitalisation.
OSR Holdings Inc - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how OSR Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
OSR Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OSR Holdings Inc ranked by their cash flow conversion efficiency. Explore OSR Holdings Inc (OSRH) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Intelicanna Ltd
TA:INTL
|
-0.023x |
|
Curative Biotechnology Inc
NYSE MKT:CUBT
|
0.031x |
|
BHB Brauholding Bayern-Mitte AG
F:B9B
|
N/A |
|
Mountain Lake Acquisition Corp. Right
NASDAQ:MLACR
|
N/A |
|
Intelligent Bio Solutions Inc.
NASDAQ:INBS
|
-0.831x |
|
Lodestar Minerals Ltd
AU:LSR
|
3.339x |
|
Indal Aluminium Industry Tbk
JK:INAI
|
-1.201x |
|
Gix Internet Ltd
TA:GIX
|
N/A |
Annual Cash Flow Conversion Efficiency for OSR Holdings Inc (2020–2025)
The table below shows the annual cash flow conversion efficiency of OSR Holdings Inc from 2020 to 2025. View OSR Holdings Inc (OSRH) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $127.04 Million | $-4.33 Million | -0.034x | -110.10% |
| 2024-12-31 | $-6.49 Million | $-2.19 Million | 0.337x | +60.97% |
| 2023-12-31 | $-3.91 Million | $-818.77K | 0.210x | +4126.21% |
| 2022-12-31 | $78.77K | $-410.00 | -0.005x | -102.39% |
| 2021-12-31 | $-2.12K | $-461.00 | 0.217x | +101.08% |
| 2020-12-31 | $1.19K | $-23.81K | -20.044x | -- |
About OSR Holdings Inc
OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tu… Read more